Development of Novel 4-Arylpyridin-2-one and 6-Arylpyrimidin-4-one Positive Allosteric Modulators of the M1 Muscarinic Acetylcholine Receptor

ChemMedChem. 2021 Jan 8;16(1):216-233. doi: 10.1002/cmdc.202000540. Epub 2020 Sep 25.

Abstract

This study investigated the structure-activity relationships of 4-phenylpyridin-2-one and 6-phenylpyrimidin-4-one M1 muscarinic acetylcholine receptor (M1 mAChRs) positive allosteric modulators (PAMs). The presented series focuses on modifications to the core and top motif of the reported leads, MIPS1650 (1) and MIPS1780 (2). Profiling of our novel analogues showed that these modifications result in more nuanced effects on the allosteric properties compared to our previous compounds with alterations to the biaryl pendant. Further pharmacological characterisation of the selected compounds in radioligand binding, IP1 accumulation and β-arrestin 2 recruitment assays demonstrated that, despite primarily acting as affinity modulators, the PAMs displayed different pharmacological properties across the two cellular assays. The novel PAM 7 f is a potential lead candidate for further development of peripherally restricted M1 PAMs, due to its lower blood-brain-barrier (BBB) permeability and improved exposure in the periphery compared to lead 2.

Keywords: allosteric ligands; modulators; muscarinic acetylcholine receptor.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Allosteric Regulation / drug effects
  • Animals
  • Blood-Brain Barrier / drug effects
  • Blood-Brain Barrier / metabolism
  • Half-Life
  • Humans
  • Mice
  • Permeability / drug effects
  • Pyridones / chemistry*
  • Pyridones / metabolism
  • Pyridones / pharmacology
  • Receptor, Muscarinic M1 / chemistry
  • Receptor, Muscarinic M1 / metabolism*
  • Structure-Activity Relationship

Substances

  • 4-phenylpyridin-2-one
  • Pyridones
  • Receptor, Muscarinic M1